Objective: Concerns of breast cancer risk in postmenopausal women taking combined estrogen + progestin therapy have generated interest in the use of selective estrogen receptor modulators (SERMs) as potential progestin alternatives. Endometrial proliferation and cancer risk are major concerns, however, for estrogens and certain types of SERMs when given alone. The primary aim of this study was to evaluate the endometrial profile of bazedoxifene acetate (BZA), a third-generation SERM, alone and in combination with conjugated equine estrogens (CEE) in a postmenopausal primate model.
E strogen-alone therapy (ET) alleviates menopausal symptoms and reduces osteoporosis and fracture risk in aging women. 1<3 However, long-term use of ET, even at low doses, has been associated with an increased risk of endometrial hyperplasia and endometrial cancer. 4<7 To date, progestin cotherapy has been the only clinical strategy for effectively preventing estrogen-induced endometrial proliferation and for lowering cancer risk. 6, 8 Historically, the most commonly prescribed estrogen + progestin therapy (EPT) in the United States has been conjugated equine estrogens (CEE) given with medroxyprogesterone acetate (MPA). 9 However, primary results from the Women's Health Initiative randomized clinical trial 10 and prior observational studies 11 have associated long-term CEE + MPA cotherapy with an increased risk of breast cancer and a higher incidence of gynecological surgical operations (eg, hysterectomies) caused by increased uterine bleeding. 12 Consequently, there has been increased interest in new menopausal therapies that provide comparable efficacy to ET without adverse proliferative effects on the breast and endometrium.
Recently, selective estrogen receptor modulators (SERMs) have been proposed as an alternative to the progestin component in EPT. 13 As a class of nonsteroidal compounds, SERMs bind to estrogen receptors (ERs) > and A and induce a mixed pattern of ER agonist and antagonist responses, depending on the particular SERM and target tissue. 14 Current SERMs include tamoxifen and raloxifene, which are widely used in the prevention of breast cancer. 15 Similar to ET, most SERMs increase bone mineral density and improve lipid profiles. However, in contrast to ET, current SERMs given alone do not treat menopausal symptoms and, in some cases, worsen them. 16<18 The ideal clinical goal of combining a SERM with ET would be to selectively retain the benefits of both agents while reducing the adverse effects of either agent alone. The estrogen component of such a combination would relieve hot flushes, improve urogenital atrophy, and prevent bone loss, whereas the SERM component would help maintain bone mass and provide antiestrogenic effects on the breast and endometrium. Information on the uterotropic effects of the SERM component is critical considering that SERMs, such as tamoxifen, have been associated with an increased incidence of endometrial cancer and other adverse morphologic changes such as stromal fibrosis, cystic change, and polyp formation. 16, 19, 22 Bazedoxifene acetate (BZA; 20 mg/d) is an indole-based SERM currently undergoing evaluation for the treatment of osteoporosis and, in combination with CEE (0.45 and 0.625 mg/d), for the reduction of menopausal symptoms and the prevention of osteoporosis. 23<26 The purpose of this study was to investigate the endometrial safety profile of BZA alone and in combination with CEE in a randomized multisystem nonhuman primate translational trial. We hypothesized that BZA would antagonize the proliferative and transcriptional effects of CEE on the endometrium, whereas BZA would have minimal estrogen agonist effects when administered alone. Effects on other systems, including breast, bone, and the cardiovascular system, will be reported elsewhere.
METHODS

Study design and treatments
This preclinical trial followed a parallel-arm study design in which 98 ovariectomized adult cynomolgus macaques (Macaca fascicularis) were randomized by social group to receive one of the following four treatments for 20 months: (i) no treatment (controls; n = 23), (ii) BZA 20 mg (n = 24), (iii) CEE 0.45 mg (n = 24), or (iv) the combination of BZA 20 mg + CEE 0.45 mg (n = 27). An important feature of this design is the inclusion of a CEE-alone group as positive control, which was not feasible in previous clinical trials because all participating women did not have prior hysterectomy. 26 All monkeys were imported from the Indonesian Primate Center (Pusat Studi Satwa Primata) at the Institut Pertanian Bogor (Bogor, Indonesia). After quarantine, all monkeys were placed in stable social groups consisting of two to five animals; the groups were approximately equivalent in body weight. Social groups were randomly assigned a treatment condition using a simple randomization procedure. Each group originally consisted of 25 animals to achieve adequate power for the cardiovascular endpoints (published elsewhere) in this preclinical trial. However, two animals were added to the BZA and BZA + CEE groups to account for any exclusions or deaths during the study. Subsequently, two animals from the control group and three animals from the BZA group were excluded owing to elevated serum ovarian hormone levels indicating the presence of ectopic ovarian tissue (follicles, luteal tissue, and/or stroma found outside the ovary). 27 Another monkey from the CEE group was euthanized owing to intussusception.
An important rationale for the use of the macaque model in this trial is the high degree of similarity in pathophysiology 28 and responses to hormonal agents 29 between the human endometrium and the macaque endometrium. All monkeys were considered monoparous or multiparous based on clinical records from the original breeding colony. Procedures involving these animals were approved by the Institutional Animal Care and Use Committee of Wake Forest University and conducted in accordance with federal, state, and institutional guidelines. The facilities and animal resources program of Wake Forest University are fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care.
Hormone treatments were administered in a standard isoflavone-free casein + lactalbumin control diet and fed once daily for 20 months. The standard control diet was formulated to model the high-cholesterol (0.29 mg/Cal) and high-fat (35% of calories from fat) diets typically consumed by postmenopausal women in the United States. Studies conducted to determine CEE and BZA doses for female macaques that were equivalent to women's daily dose of CEE 0.45 mg and BZA 20 mg have been published elsewhere. 30 Briefly, drug doses were determined based on energy intake to account for differences in metabolic rates between female monkeys and women, as well as plasma concentrations measured in postmenopausal women receiving BZA 20 mg/day. 31 Animals in the CEE-treated groups were given CEE 0.03 mg/kg body weight/day, whereas those animals in the BZA-treated groups received BZA 2.5 mg/kg body weight/day.
Circulating estrogen and BZA concentrations
As part of the main study, plasma estrone (E 1 ), 17A-estradiol (E 2 ), and BZA concentrations were obtained 4 hours immediately after a meal and after an overnight fast to confirm adequate dosing and dietary intake. These results have been reported elsewhere. 30 Repeated measurements of E 1 and E 2 were also performed in a randomly selected subset of animals (n = 47) after an 18-hour fast on the day of necropsy, and these values are reported here. E 1 and E 2 concentrations were measured at the Wake Forest University Primate Center Clinical Laboratory using commercially available radioimmunoassay kits (Siemens/DPC), whereas plasma BZA concentrations were measured at Pfizer using high-performance liquid chromatography with fluorescence detection. The lower limit of quantification was 2.5 pg/mL for E 1 and E 2 , and 1.0 ng/mL for BZA. Serum used to measure E 2 concentrations was first extracted with ethyl ether, and extracts were dried and reconstituted with zero standard serum.
Uterine area via uterine ultrasounds
Transabdominal ultrasounds were conducted using a Sonosite MicroMaxx portable ultrasound machine with a 6.0-MHz linear transducer (Sonosite, Bothell, WA) at baseline (4 wk after ovariectomy) and after 6, 12, and 20 months of treatment. For each timepoint, at least three static digital images were captured at the maximal transverse cross-sectional area of the uterus. Measurements of uterine area (cm 2 ) were made using public domain software (National Institutes of Health ImageJ 1.34; http://rsb.info.nih.gov/ij/upgrade/). 32 All sonographic images were obtained and measured by the same person blinded to the treatment groups.
Histomorphometry and histopathology
At necropsy, uteri were collected, weighed, and prepared for histology. 32 Percentage of epithelial area and mean endometrial thickness were quantified using H&EYstained slides and morphometry techniques similar to those described previously. 22, 33 Briefly, epithelial area was determined by manual tracing of glandular units (minus luminal areas) within the superficial and basal endometrium and expressed as a percentage of the total area examined (Image-Pro Plus software; Media Cybernetics, Silver Spring, MD). Mean endometrial thickness (superficial + basal) was measured in a similar manner. H&EYstained slides were also evaluated for evidence of glandular hyperplasia (simple and complex), stromal hyperplasia, stromal edema, cystic dilation, and other histological lesions by a board-certified veterinary pathologist (C.E.W.). Stromal edema and cystic dilation are considered low-risk morphologic changes associated with exogenous estrogen exposure. 29 Endometrial stromal fibrosis (collagen content) was quantified from slides stained with Masson's trichrome (containing Weigert's iron hematoxylin, Crocein Scarlet MOO, 5% aqueous phosphomolybdic acid, and aniline blue; Fisher Scientific and Sigma) using a selective color-based analysis in the Image Pro-Plus Software. 22 Blue-stained areas in the superficial endometrial stroma represented collagen, whereas red-stained areas represented stromal cell nuclei and cytoplasm. The area of stromal edema and undefined (pale blue) ground substance was estimated by subtracting the total area examined by the blue-and red-strained areas. All histomorphometry and histopathological evaluations were completed by persons blinded to the treatment groups.
Immunohistochemistry
Immunohistochemistry (IHC) was performed on fixed endometrial sections using commercially available primary monoclonal antibodies for the proliferation marker Ki67 (Ki67SP6; Thermo Scientific, Fremont, CA) and the sex steroid receptors ER-> (NCL-ER-6F11, Novocastra Reagents; Leica Microsystems Inc., Buffalo, NY) and progesterone receptor (PGR; NCL-PGR-312, Novocastra Reagents; Leica Microsystems Inc.), as described previously. 30 Nuclear immunolabeling within the superficial and basal endometrium was quantified using a computer-assisted manual counting technique with a grid filter to select cells for counting (Image-Pro Plus software; Media Cybernetics). An H score was calculated using the equation (3 Â % strongly stained nuclei) + (2 Â % moderately stained nuclei) + (% weakly stained nuclei). 34 IHC quantification was performed by a technician blinded to the treatment groups.
Quantitative real-time polymerase chain reaction
Expression of genes related to cell proliferation (MKI67, Ki67 antigen) and ER activity (ESR1, ER->; ESR2, ER-A; PGR, PGR; TFF1, trefoil factor 1 [pS2]) was determined by quantitative real-time polymerase chain reaction (qRT-PCR) using techniques described elsewhere. 30 Briefly, all qRT-PCRs were run with Applied Biosystems (ABI) TaqMan primer probe sets and performed on an ABI 7500 Fast Real-Time PCR System (ABI, Carlsbad, CA). A-Actin was used as endogenous control, whereas reference endometrial tissue complementary DNA was run in parallel for plate-to-plate calibration. 32 The reliability of A-actin as an internal control was evaluated using analysis of variance, analyses of the SD of C t , and change in the C t of A-actin between control and treatment samples. The relative expression of each target gene was calculated using ABI Relative Quantification 7500 Software version 2.0.1.
Statistical analyses
All variables were evaluated for their distribution and equality of variance. Data not normally distributed were transformed (log 10 or square root) to improve normality for analysis and reverse transformed to the original scale for display in the results. The following data violated Levene's test for equality of variance and were analyzed using the nonparametric Kruskal-Wallis test and the post hoc Wilcoxon (rank sum) test: uterine weights, E 2 concentrations, (superficial) epithelial area, (superficial) luminal area, all qRT-PCR assays except for ESR1 and ESR2, and IHC for Ki67 (superficial glands and stroma) and ER-> (superficial glands). Significance levels were adjusted for multiple pairwise comparisons using Bonferroni correction. Differences in uterine area and body weight among the treatment groups were determined using a mixed-model approach with baseline values as covariate. For each variable, this model allowed for a within-group comparison at each posttreatment period and a between-timepoint comparison within each group (eg, 20-mo posttreatment values compared with baseline). Fisher's exact test was used to evaluate treatment group differences in the prevalence of histopathological findings. The remaining data were assessed using analysis of variance and Tukey honestly significant difference post hoc test for multiple pairwise comparisons. A two-tailed significance level of 0.05 was selected for all comparisons, and all analyses were performed using JMP statistical software version 9.0.2 (SAS Institute Inc., Cary, NC).
RESULTS
Treatment group characteristics
Treatment group characteristics, including age, body weights, and hormone concentrations, are summarized in Supplemental Digital Content 1 (Table, http://links.lww.com/MENO/A44). At baseline, the mean estimated age of all animals was 12.7 years (range, 9-18 y), with no between-group differences (P 9 0.1). All groups showed a small increase in body weight from baseline to 20 months after treatment. This gain in body weight reached significance only in the control group (P G 0.001), with a trend toward significance in the BZA group (P = 0.06). After 20 months of treatment, the BZA + CEE group weighed significantly less than the control group (P G 0.01); however, no significant differences in body weight and plasma estrogen (E 1 and E 2 ) concentrations were noted between the BZA + CEE group and the CEE group (P 9 0.1 for all).
Uterine area via transabdominal ultrasound
Uterine area among CEE-treated animals increased progressively from baseline to 20 months after treatment (P G 0.0001) and was significantly greater than the control group at 6, 12, and 20 months of treatment (P G 0.0001 for all; Fig. 1 ). The BZA + CEE and BZA groups had significantly smaller uterine areas relative to the CEE group (P G 0.0001 for all) and similar uterine areas compared with controls at each posttreatment timepoint (Fig. 1 ).
Endometrial thickness, epithelial area, and proliferation
After 20 months of treatment, uterine weight and endometrial thickness among the control, BZA, and BZA + CEE groups were comparable and 2.5-to 3.5-fold lower than the CEE group (P G 0.0001 for all vs CEE; Fig. 2A, B) . Similarly, epithelial area within the superficial endometrium was not significantly different among the control, BZA, and BZA + CEE groups and measured 1.5-to 2.0-fold less than the CEE group (P G 0.0001 for all vs CEE; Fig. 2C ). Epithelial area specifically within the basal endometrium was also significantly less in the BZA + CEE and BZA groups than in the CEE group (P G 0.0001 for both) but 44% higher than controls (P G 0.01 for both).
The addition of BZA to CEE significantly inhibited CEEinduced endometrial proliferation, indicated by lower MKI67 gene expression and Ki67 immunolabeling in the superficial glands and stroma for the BZA + CEE group compared with the CEE group (P G 0.001 for all; Fig. 3A, B) . Proliferation in the superficial glands was also lower for the BZA + CEE group compared with controls (P G 0.01; Fig. 3B ). Treatment with BZA alone did not induce MKI67 expression ( Fig. 3A) or Ki67 immunolabeling in the superficial or basal endometrial glands (Fig. 3B , C) but resulted in 3-fold higher Ki67 immunoreactivity in the basal stroma compared with controls (P = 0.04; Fig. 3C ). Representative photomicrographs of Ki67 immunolabeling for BZA, CEE, BZA + CEE, and no hormone treatment are displayed in Supplemental Digital Content 4 (http://links.lww.com/MENO/A47).
Endometrial morphology
The addition of BZA to CEE also inhibited estrogeninduced changes in endometrial morphology. The prevalence of simple glandular and stromal hyperplasia was higher in the CEE group (P G 0.0001 vs the control and BZA + CEE groups) but not in the BZA and BZA + CEE groups (Table 1) . Similarly, the prevalence of stromal edema and cystic dilation in the endometrial glands was most evident in the CEE group (Table 1) . These findings were confirmed using quantitative morphometric measurements shown in Figure 4A , B. Treatment with BZA + CEE and BZA had no significant effect on endometrial collagen content compared with controls, but treatment with CEE resulted in significantly more collagen compared with the other groups (P G 0.01 for all; Fig. 4C ). Incidental histological findings included vascular remodeling (adventitial expansion) associated with prior pregnancy. No 
ER-> expression and transcriptional activation
Treatment with BZA, CEE, and BZA + CEE altered endometrial ER-> immunolabeling (Fig. 5A, B ) but not gene expression (graph A, Supplemental Digital Content 2, http://links.lww.com/MENO/A45). Groups treated with BZA + CEE and BZA had significantly less glandular and stromal ER-> immunolabeling in the superficial and basal endometrium compared with the control and CEE groups (P G 0.0001 to P G 0.05 for all vs the control and CEE groups). Treatment with CEE resulted in significantly lower ER-> immunolabeling in the basal stroma compared with controls (P G 0.05) but greater ER-> immunoreactivity relative to BZA + CEE (P G 0.05). Unlike ER-> gene expression, ER-A messenger RNA expression was significantly decreased by CEE treatment (P G 0.0001 vs controls; graph B, Supplemental Digital Content 2, http://links.lww.com/MENO/A45).
As expected, CEE treatment significantly induced the expression of the estrogen response genes TFF1 and PGR compared with controls (P G 0.001 for both; Fig. 5C, D) . The addition of BZA to CEE significantly attenuated these effects (P G 0.001 for both), whereas BZA alone had no effect. Glandular and stromal PGR immunolabeling within the endometrium showed a similar pattern (graphs A and B, Supplemental Digital Content 3, http://links.lww.com/MENO/A46).
DISCUSSION
Traditional hormone therapies are associated with increased cancer risk in the endometrium (ET) and breast (EPT) in postmenopausal women. Estrogen + SERM cotherapies are emerging as potential alternatives to these traditional therapies. Endometrial stimulation and cancer risk are major concerns, however, for both estrogens and certain types of SERMs when given alone, and limited data on the endometrial safety of estrogen + SERM cotherapies exist. In this preclinical trial, we investigated the endometrial risk profile of a new SERM, BZA, given alone and with CEE, the most widely prescribed ET in the United States. 9 Treatment with CEE increased uterine size, endometrial thickness, epithelial area, proliferation, and gene markers of ER-> activity, whereas the addition of BZA to CEE significantly antagonized these effects. Treatment effects of BZA alone were comparable to controls. These findings show for the first time that BZA is a clear estrogen antagonist in the endometrium at clinically relevant doses.
Here, the full inhibition of CEE effects by BZA supports data from phase III clinical trials suggesting that BZA + CEE cotherapy does not have tamoxifen-like uterotropic effects on postmenopausal women. 35, 36 In a 2-year study of osteoporotic postmenopausal women (Selective estrogens, Menopause, And Response to Therapy [SMART] 1), endometrial hyperplasia (evaluated via biopsy) and uterine bleeding incidences with BZA 20 mg, combined with either CEE 0.45 mg or CEE 0.625 mg, were not significantly different from placebo. 35, 36 Similarly, preliminary data from another smaller 1-year trial (SMART-5) reported comparable incidences of endometrial hyperplasia among women receiving BZA 20 mg + CEE 0.45 mg (0.3%) and BZA 20 mg + CEE 0.625 mg (0.27%) relative to women receiving MPA 1.5 mg + CEE 0.45 mg (0%), BZA 20 mg monotherapy (0%), and placebo (0%). 37 Evidence from prior reports, however, suggests that the inhibitory effects of BZA on ER activity may differ according to the dose and/or type of estrogen used in BZA + estrogen therapies. For example, cell culture studies showed that 10 nM BZA completely inhibits the growth of E 2 -stimulated MCF-7 breast cancer cells, whereas 1.0 pM BZA results in negligible inhibition. 38 Similarly, in the 2-year SMART-1 trial, the uterotropic effects of CEE (0.45 or 0.625 mg/d) were effectively antagonized with BZA 20 mg/day, but not with BZA 10 mg/day. 35 To date, the interactive effects of estrogens and BZA on the breast and endometrium have only been evaluated with oral CEE as the primary ET 30,35<37,39 ; therefore, it is not known whether the target dose of BZA (20 mg/d) would prevent endometrial and breast proliferation if coadministered with standard doses of other ETs, such as oral and transdermal E 2 .
Few prior studies have evaluated the endometrial effects of estrogen + SERM therapies. In one small study evaluating the combination of raloxifene (60 mg/d) and oral E 2 (1 mg/d) in postmenopausal women transitioning from EPT, the frequencies of vasomotor symptoms, hot flushes, and night sweats were significantly reduced compared with baseline and raloxifene monotherapy. 40 However, this combination was associated with increased endometrial thickness and two cases of atypical endometrial hyperplasia. Similarly, another pilot study found significantly less vasomotor events but increased endometrial thickness with concomitant use of oral raloxifene and a transdermal E 2 patch. 41 Results from a rodent study suggested that BZA has greater ER antagonist activity than raloxifene in the endometrium and may inhibit proliferation if coadministered with E 2 , 42 but this observation has not been tested in a randomized clinical trial or at clinically relevant doses of BZA and E 2 . It is also worth noting that some estrogen + SERM combinations have shown mixed agonist and antagonist effects on the endometrium. In a prior macaque study, the addition of tamoxifen to low-dose E 2 therapy inhibited E 2 -induced proliferation and expression of genes related to cell cycle progression, but still induced stromal fibrosis, cystic change, and increases in endometrial thickness similar to tamoxifen-alone therapy. 22 We have previously reported that BZA with and without CEE reduces ER-> immunolabeling in the breast. 30 As reported here, a similar observation was noted in the endometrium in which both glandular and stromal ER-> immunolabeling were significantly less with BZA and BZA + CEE treatments compared with control and CEE treatment, whereas ER-> gene expression was not affected. These unanticipated results suggest that BZA may increase ER-> turnover, besides blocking estrogen binding. This hypothesis is supported by a recent breast cancer cell study that showed proteasomemediated degradation of ER-> by BZA. 43 However, further studies should be conducted to confirm that BZA may increase ER-> ubiquitation and degradation in normal endometrial cells.
CONCLUSIONS
Exposure to estrogens is a key risk factor for endometrial cancer. In postmenopausal women, exogenous ET leads to increased endometrial proliferation, hyperplasia, and up to a 5-fold higher incidence of cancer. 1, 44, 45 Our results show that BZA at the target human equivalent dose fully antagonizes the proliferative and transcriptional effects of CEE on the macaque endometrium while having no estrogen agonist activity when given alone. This information should be useful in the planning of future SERM + estrogen clinical trials and to symptomatic postmenopausal women seeking alternatives to traditional estrogen + progestin therapies.
